

Beaumont

Origination 6/15/2022
Last Approved 7/17/2024
Effective 7/21/2024
Last Revised 7/17/2024
Next Review 7/17/2026

Document Contact Kelly Sartor: Mgr, Division Laboratory
Area Laboratory-Blood Bank
Applicability All Beaumont Hospitals

Roles and Responsibilities of Medical Director for Transfusion Reaction Evaluations

Document Type: Procedure

I. PURPOSE AND OBJECTIVE:

This document is to provide guidance to the Blood Bank staff on the responsibilities of the Blood Bank Medical Director.

II. DEFINITIONS

A. **Designee:** any blood bank technical director, or transfusion medicine fellow.

III. GENERAL INFORMATION:

A. **The Blood Bank Medical Director or designee shall:**

1. Immediately notify the patient's physician of a suspected case of a hemolytic transfusion reaction, bacterial contamination, or other serious reaction.
2. Perform a prompt and complete adverse reaction investigation report that includes an interpretation and evaluation. The complete report will be entered in the patient's electronic medical chart in the Hospital Information System (HIS).
3. Safeguard that criteria exist for the recognition of adverse reactions to blood components, and will verify that documentation exists of periodic in-service education on the recognition of adverse reactions.
4. Safeguard that documented procedures are in place that require adverse reactions to be reported to the Blood Bank immediately, and that these procedures describe appropriate actions to be taken in the event of an adverse reaction. See [Blood](#)

Component/Product Administration: Adult and Pediatric Patients.

5. Be involved in the investigation and resolution of all adverse reactions or transfusion-related incidents involving a system failure (e.g., misadministration of a blood component).
6. Establish documented procedures that indicate when additional testing is required based on the initial findings of the transfusion reaction evaluation.
7. Interpret and report the findings of the transfusion reaction evaluation in a timely and effective manner. A partial notification will generally occur on the next business day and will be entered in the patient's electronic medical chart in the HIS. However, direct notification to the patient's physician may occur sooner if a serious transfusion reaction has occurred. The final report will be entered once the blood component's culture results, if applicable, are available.
8. Notify the blood supplier if a blood component is suspected as the primary cause of an adverse reaction (e.g., transfusion-related acute lung injury (TRALI) or transfusion-related infection), and document this notification in the transfusion reaction report.
9. Certify protocols exist which manage quarantines, recalls, and market withdrawals issued by blood suppliers, and which identify and quarantine blood components when notice is received that a donor tests positive for an infectious disease.
10. Establish protocols to evaluate adverse effects of transfusion, including follow-up for transfusion-transmitted diseases and delayed transfusion reactions.
11. Establish a detailed procedure, consistent with Food and Drug Administration (FDA) and Centers for Medicare & Medicaid Services (CMS) guidelines and regulations, to notify and counsel recipients of potentially infectious blood components.
12. Notify the patient's physician if growth is detected in any component sent to the Microbiology Laboratory. This notification will be documented in the transfusion reaction report.
13. Notify the FDA in writing within seven (7) days of a fatal reaction. Notification shall be made by telephone, facsimile, or express or electronic mail "as soon as possible" after the event, followed up with a written report within seven (7) days.
14. Develop a plan to reduce the risk of transfusion-related acute lung injury (TRALI). The Blood Bank Medical Director or designee will
 - a. Track the frequency of TRALI and report cases and implicated donors to the blood supplier.

Approval Signatures

Step Description

Approver

Date

Kristina Davis: Staff Physician

7/17/2024

Policy and Forms Steering Committee (if needed)	Hassan Kanaan: OUWB Clinical Faculty	7/17/2024
	Muhammad Arshad: Chief, Pathology	7/17/2024
	Jeremy Powers: Chief, Pathology	7/17/2024
	Ann Marie Blenc: System Med Dir, Hematopath	7/17/2024
	Ryan Johnson: OUWB Clinical Faculty	7/16/2024
	Masood Siddiqui: Staff Pathologist	7/16/2024
	John Pui: Chief, Pathology	7/16/2024
	Kelly Sartor: Mgr, Division Laboratory	7/16/2024
	Kristen DiCicco: Mgr, Laboratory	7/16/2024
	Fatima Bazzi: Medical Technologist Lead	7/16/2024
	Katherine Persinger: Mgr, Laboratory	7/16/2024
	Karrie Torgerson: Medical Technologist Lead	7/13/2024
	Hilary Morey: Medical Technologist Lead	7/12/2024
	Ashley Beesley: Mgr, Laboratory	7/12/2024
	Suzanne Chahine: Medical Technologist Lead	7/12/2024
	Teresa Lovins: Supv, Laboratory	7/12/2024
	Kelly Sartor: Mgr, Division Laboratory	7/11/2024
	Kelly Sartor: Mgr, Division Laboratory	7/11/2024

Applicability

Dearborn, Farmington Hills, Grosse Pointe, Royal Oak, Taylor, Trenton, Troy, Wayne